We’re excited to announce a strategic alliance between ExSyn and simAbs, a pioneering EU- based developer of ATMPs and biologics. Through ExSyn—now representing simAbs in Asia as well as in the US —the partnership brings next-generation antibodies, built on patented continuous-flow technology, to researchers, biotech firms, and healthcare providers.
About simAbs: Smart Integrated Manufacturing of ATMP’s and Biologics
simAbs, based in Belgium, offers a Smart Integrated Manufacturing platform for small-scale, flexible biologics production—from mg to kg—leveraging continuous bioprocessing for both monoclonal and complex antibody formats (e.g., bispecifics, Fab fragments).
Core Capabilities
• Continuous bioprocessing with steady-state perfusion lasting up to 60 days
• Integrated unit operations: Upstream + downstream processes in a single, automated pipeline
• EU-GMP accredited production of monoclonal antibodies (mAbs) and complex biological molecules, ensuring consistent quality from clinical development through to commercial-scale manufacturing
What This Collaboration Delivers
• Market access: ExSyn opens avenues in Asia (and Exim-Indis covers the U.S.),
broadening simAbs’ reach.
• Tailored supply: Small-batch, rapid-turnaround antibody production supports early- stage research.
• Seamless integration: From cell line development to GMP manufacturing, exSyn and simAbs offer end-to-end biologics support.
A Glimpse Ahead
This collaboration marks a major step toward delivering advanced, scalable biologics by combining simAbs’ innovative manufacturing with ExSyn’s Asian distribution network.
For more information about simAbs, please visit www.simabs.com. To discuss your biotechnology needs/product enquiries, feel free to write to us at sourcing@exsyncorp.com.